Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript

Pulse Biosciences reported Q1 GAAP net loss of $16.8 million, wider than $10.1 million a year ago, as costs and expenses rose to $18.0 million from $10.6 million. Despite heavier spending, the company ended March with $119.3 million in cash, boosted by $14.1 million from warrant exercises, and advanced multiple nsPFA clinical programs, including 100 patients treated in the 360 catheter feasibility study and over 90 patients in the thyroid pilot. Management expects commercial use of the thyroid nodule device in the second half of 2025 and plans to initiate pivotal IDE studies later this year.

Analysis

PLSE is at the classic pre-commercial inflection where the equity story is increasingly about execution velocity rather than technology validation. The near-term positive is that multiple clinical readouts reduce single-program risk, but the more important second-order effect is that each incremental site and investigator creates a distribution channel for future revenue without proportional salesforce scaling. That makes the setup asymmetric if workflow conversion in thyroid nodules actually begins in the second half, because the market is likely underestimating how quickly clinical champions can become repeat purchasers once reimbursement and procedural cadence stabilize.

The biggest hidden risk is not clinical efficacy; it is operational slippage between promising data and repeatable commercial adoption. A device company can look “de-risked” on endpoints while still stalling on utilization if physician training, room-time economics, or reimbursement prove sticky, and that gap usually shows up over the next 2-3 quarters rather than immediately. Also, the expense ramp is likely to keep outrunning visible revenue through at least mid-year, so any disappointment in IDE timing or pilot-to-commercial conversion could compress the multiple sharply.

Competitive dynamics favor incumbents with large EP distribution and hospital relationships if PLSE’s pivotal timelines drift, but there is also a potential platform effect: positive nsPFA data can pressure adjacent ablation vendors and accelerate physician attention toward pulse-field-based workflows more broadly. The contrarian angle is that the market may be too focused on “cash runway” and too little on the fact that warrant exercise funded optionality without forcing near-term dilution, giving management a cleaner window to convert clinical momentum into a commercial launch. That means the stock can trade well on forward catalysts even before revenue inflects, but only if the next 1-2 catalyst windows hit on schedule.

Key Decisions for Investors

• Long PLSE tactically into the next catalyst window (clinical update / IDE filing timing) with a 1-3 month horizon; thesis is that optionality is underpriced while cash is sufficient to avoid a near-term balance-sheet overhang.
• Buy PLSE Jan-2026 calls or call spreads to express asymmetric upside from commercialization conversion, while capping downside if pilot users fail to convert into repeat commercial accounts.
• Pair trade: long PLSE / short a larger-cap electroporation beneficiary basket if available, betting that early-stage data momentum and launch optionality are not fully reflected in PLSE vs. more mature peers.
• If PLSE trades higher on any delay-free catalyst, take partial profits into strength; the key risk is a 2-3 quarter execution gap where opex stays elevated but revenue remains immaterial.
• Avoid adding aggressively on a single data headline alone; wait for evidence of commercial repeat usage in thyroid nodules, since that is the first real proof point for revenue quality.